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ABSTRACT
Allergic rhinitis (AR), the most common chronic disease
in childhood is often ignored, misdiagnosed and/or
mistreated. Undertreated AR impairs quality of life,
exacerbates asthma and is a major factor in asthma
development. It can involve the nose itself, as well as
the organs connected with the nose manifesting a
variety of symptoms. Evidence-based guidelines for AR
therapy improve disease control. Recently, paediatric AR
guidelines have been published by the European
Academy of Allergy and Clinical Immunology and are
available online, as are a patient care pathway for
children with AR and asthma from the Royal College of
Paediatrics and Child Health. Management involves
diagnosis, followed by avoidance of relevant allergens,
with additional pharmacotherapy needed for most
sufferers. This ranges, according to severity, from saline
sprays, through non-sedating antihistamines, oral or
topical, with minimally bioavailable intranasal
corticosteroids for moderate/severe disease, possibly plus
additional antihistamine or antileukotriene. The concept
of rhinitis control is emerging, but there is no universally
accepted deﬁnition. Where pharmacotherapy fails,
allergen-speciﬁc immunotherapy, which is uniquely able
to alter long-term disease outcomes, should be
considered. The subcutaneous form (subcutaneous
immunotherapy) in children has been underused because
of concerns regarding safety and acceptability of
injections. Sublingual immunotherapy is both efﬁcacious
and safe for grass pollen allergy. Further studies on
other allergens in children are needed. Patient, carer and
practitioner education into AR and its treatment are a
vital part of management.
INTRODUCTION
Rhinitis, which can be allergic, infectious or neither
of these, is deﬁned as at least two nasal symptoms,
including rhinorrhoea, blockage, sneezing and
itching. It is a common problem in childhood and
adolescence which impacts negatively on physical,
social and psychological well-being.
Allergic rhinitis (AR) is an under-recognised
inﬂammatory condition of the nasal mucosa, caused
by immunoglobulin E (IgE)-mediated early-phase
and late-phase hypersensitivity responses, usually to
inhalant allergens, similar to those in allergic
asthma.1–3 Typical allergens include house dust
mite, grass and tree pollens, dander from animals
such as cat, dog, horse and, occasionally, moulds.4
Different phenotypes exist; those with obvious
symptoms of sneezing and running, who are easily
recognised, and others with predominant blockage,
where the diagnosis may be missed. Children with
AR can present with symptoms related to nasal con-
nections, such as lungs, throat, ears, (table 1) or to
quality-of-life impairment, often related to poor
quality sleep and consequent fatigue, poor concen-
tration and school performance.
AR is often part of a systemic inﬂammatory
process associated with other inﬂammatory condi-
tions, including allergic conjunctivitis (AC), rhinosi-
nusitis and asthma. Asthma shows an increased
prevalence in children with both allergic5 and non-
allergic rhinitis.6 A higher prevalence of asthma is
found among those suffering from persistent and
more severe rhinitis.7Over three-quarters of chil-
dren with asthma also have AR8 which is associated
with poor asthma control.9 10 Minimal persistent
allergic inﬂammation of the nasal mucosa11 syner-
gises with infective inﬂammation; thus, subjects
with AR have more problems with viral colds,12
and the combination in children of allergic sensi-
tisation, relevant allergen exposure and viral cold
gives a high risk for hospital admission for asthma
in children.13 Poor asthma control is found in chil-
dren with moderate to severe rhinitis, which should
be identiﬁed and treated.1 9 10
AR precedes asthma development in preadoles-
cence, adolescence or adult life and carries a three-
fold risk of it persisting into middle age.14 Bronchial
hyper-responsiveness, raised exhaled nitric oxide
and reduced lung function have been observed in
children with AR.15
Pharmacotherapy for AR improves asthma
control;16 17 allergen-speciﬁc immunotherapy (SIT)
for rhinitis may decrease the progression of rhinitis
to asthma.18
Rhinitis affects well-being, both physical and psy-
chological,19 20 with a direct relationship to allergen
exposure.21 Family dynamics can be disturbed.22
Uncontrolled AR reduces sleep quality23 impairing
concentration, school attendance and performance,24
including at General Certiﬁcate of Secondary
Education (GCSE) level.25 Rhinitis health-related
quality of life is reduced, again in direct correlation
with allergen exposure.26
Sedating antihistamines further reduce learning
ability and impinge on examination results.25 27
AETIOLOGY
Environmental factors (tobacco smoke, pollution,
infections, diet) acting on a genetic background
(family history) contribute to the development of
AR which may follow earlier atopic dermatitis28
but also occurs as the initial manifestation of
allergy. Sensitisation may take place via the nose.
Local IgE production can occur without evidence
of systemic sensitisation.29
MANAGEMENT
Guideline-directed management has been shown to
improve disease control.30 The global Allergic
Rhinitis and its Impact on Asthma guideline (ARIA),1
which includes quality-of-life measures in evaluation
576 Scadding GK. Arch Dis Child 2015;100:576–582. doi:10.1136/archdischild-2014-306300
Review
group.bmj.com on September 29, 2015 - Published by http://adc.bmj.com/Downloaded from 
and treatment, and provides an evidence-based approach to treat-
ment of AR, has recently been updated using GRADE (Grading of
Recommendations, Assessment, Development and Evaluations)
methodology.31 The UK has its own guidelines, which are currently
being updated.32 More recent, speciﬁcally paediatric guidelines,
include those from the European Academy for Allergy and Clinical
Immunology (EAACI)33 and patient pathways from the Royal
College of Paediatrics and Child Health.34 The following is a syn-
opsis of their content.
Diagnosis
AR is diagnosed by detailed history, including questions about
possible asthma, and nasal examination, together with inspec-
tion of throat, ears and chest where possible, backed up by spe-
ciﬁc allergy tests, either skin prick or blood tests, for speciﬁc
IgE to allergens suggested by the history.
Clinical history: symptom type, duration and frequency and
exacerbating factors are the cornerstone for diagnosing and clas-
sifying paediatric rhinitis which is characterised by two or more
nasal symptoms: itching, sneezing, obstruction and rhinorrhoea.
The timing of these in relation to exposure to allergen (ie, spe-
ciﬁc season or animal) is highly relevant. Upon such exposure,
symptoms of AR occur in minutes and last for hours. Late-phase
symptoms can include nasal obstruction, hyposmia, postnasal
mucous discharge and nasal hyper-reactivity.35 AC occurs in
approximately 50%–70% of patients with AR6 and is the
symptom which best differentiates AR from other forms of
rhinitis.
In children, rhinitis may present via associated comorbidities
(table 1) depending on the child’s age. Nasal obstruction with
chronic mouth breathing can sometimes be the only presenting
symptom in small children: adenoidal hypertrophy and recur-
rent viral colds are frequent misdiagnoses. Adenoidal hyper-
trophy with or without sleep apnoea can, in fact, be associated
with AR, and in some studies, a response to AR treatment has
been noted with an improvement in sleep or hypoxia.36
Adenoidectomy has not been reported as improving AR,
although it may have a role in treating chronic paediatric rhino-
sinusitis.37 Otitis media with effusion and Eustachian tube dys-
function can be detected in children with AR.38 In recent years,
oral allergy syndrome (OAS), also known as pollen fruit syn-
drome, has more often been reported by patients suffering with
pollen-induced AR, although the paediatric prevalence of this
problem is uncertain.39 The history of oral pruritus and/or local
angioedema in response to fresh fruits and vegetables, for
example, apples, hazelnuts, carrots, celery and peanuts, in chil-
dren with seasonal AR can be misdiagnosed as a primary food
allergy (FA). In fact, the initial sensitisation is to pollen, with
subsequent cross-reactivity to identical molecules in fruits and
vegetables. In doubtful cases, molecular allergy diagnosis may
help to distinguish OAS from FA.39
Pan airway involvement should be considered, both in the
history and on examination.
The ARIA classiﬁcation of AR as mild intermittent, moderate to
severe intermittent, mild persistent or moderate to severe persist-
ent may also be made and used as a guide to therapy (ﬁgure 1).
This classiﬁcation has been recently validated in children through
an epidemiological survey involving 1275 children between 6 and
12 years of age.40
Rhinitis has many underlying causes. (table 2).
Approximately two-thirds of children and one-third of adult
patients with rhinitis will present with AR; the remainder have
other forms and some defy classiﬁcation (idiopathic rhinitis).1
Recurrent viral colds are more frequent in small children; AR
is more common in older ones. Unilateral symptoms, nasal
obstruction without other symptoms, mucopurulent discharge,
pain or recurrent epistaxis suggest other diagnoses including
rarer conditions that can mimic AR.35 Chronic unremitting
rhinitis present from birth should lead to tests for primary
ciliary diskinesia. One-sided persistent nasal blockage, espe-
cially with purulent discharge, suggests a foreign body or uni-
lateral choanal atresia. Watery discharge from one side of the
Table 1 Recognising rhinitis in childhood
Adapted from Roberts et al33 (with permission). Other rare causes include hormonal rhinitis in teenagers, neurogenic rhinitis and aspirin-sensitive rhinitis.
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nose, especially on bending forward, can represent a cerebro-
spinal ﬂuid leak. Cystic ﬁbrosis should be sought if nasal
polyps are found. Oral contraceptives can cause rhinitis in
adolescents.
EXAMINATION
Allergic children may give the ‘allergic salute’, rubbing their
nose upwards, leading to a crease across the nasal bridge, and
may also have an extra skin fold or line under their lower
Figure 1 The Allergic Rhinitis and
its Impact on Asthma guideline
classiﬁcation in untreated patients.2
The historical classiﬁcation of allergic
rhinitis (AR) as seasonal or perennial in
relation to triggering environmental
allergens is useful in some geographical
regions and is important for pollen
immunotherapy and has, therefore,
been additionally maintained in the
British Society of Allergy and Clinical
Immunology UK classiﬁcation of AR.1
Table 2 Differential diagnosis of rhinitis in children (level D)
Adapted from Roberts et al 33 (with permission).
CSF, cerebrospinal fluid.
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eyelids (Denny–Morgan lines). Allergic shiners (dark eye
shadows beneath the lower eye lid), caused by ﬂuid accumula-
tion in the infraorbital groove, are typical of childhood AR
being darker in severe chronic AR.41 Frequent throat clearing or
hoarseness can be another feature. Internal nasal examination,
by otoscope or endoscope, is essential, to rule out alternatives
such as nasal polyps.1 33 34
INVESTIGATIONS
Conﬁrmation of the diagnosis of AR requires evidence of speciﬁc
IgE reactivity to airborne allergens relevant to the history via
either skin-prick testing or the demonstration of serum-speciﬁc
IgE. This information is also relevant to environmental control
measures and allergen-SIT. Immediate hypersensitivity skin testing
provides results within 15 min of performing skin tests, whereas
blood tests for speciﬁc IgE take days and may be less cost-effective
than skin-prick testing, but are useful in patients with dermato-
graphism, severe atopic dermatitis or those unable or unwilling to
temporarily stop antihistamine use. All IgE test results must be
interpreted in the light of the history since both false negative and
false positive (sensitisation without clinical disease) tests
occur.29 42 43 AR is triggered mainly by inhalant allergens, of
which house dust mites, grass and tree pollens are the most
common in most parts of the world.5 It should be noted that an
isolated positive IgE test with no relevant symptoms represents
sensitisation and not clinical disease and does not require treat-
ment; therefore, ‘ﬁshing expeditions’, in which multiple allergy
tests are undertaken, are not recommended.
If IgE tests are unavailable, then a possible alternative is a trial
of antiallergy therapy using an intranasal corticosteroid or anti-
histamine or both.
Other tests measuring nasal patency and lung function may
be helpful. The latter should always be done in persistent rhin-
itis or where there are any chest symptoms.
Treatment
This aims at safe and effective symptom relief plus prevention of
complications and disease progression. There is evidence that
outcomes are improved when evidence-based guidelines are
applied.31 The ARIA guidelines are currently the most widely
used in Europe for AR treatment. A recent revision published in
2010 answers speciﬁc paediatric questions.32 The EAACI guide-
line similarly suggests a stepwise therapeutic approach (ﬁgure 2).
Allergen avoidance, where possible, is recommended across the
spectrum of disease severity. Those suffering from hay fever are
asymptomatic outside the pollen season and symptoms in nose and
eyes are reduced by nasal air ﬁlters,44 and pet avoidance shows clear
beneﬁts; for house dust mite (HDM) reduction, individual measures
gave equivocal results or lack of beneﬁt.45 FA rarely causes isolated
rhinitis, but can be relevant where there are additional gastrointes-
tinal problems, asthma and/or atopic eczema in toddlers.
Saline douching: This reduces symptoms of AR and improves
the effect of intranasal steroids (INS)46 and is effective in rhino-
sinusitis, where douching is guideline-recommended. Isotonic
solutions are well tolerated, inexpensive, easy to use, with no
evidence showing that regular, daily use adversely affects health.
Other complementary therapies, such as homeopathy, acupunc-
ture, butterbur and herbal medicines are not recommended.32
New-generation, non-sedating, antihistamines are recom-
mended alone for mild to moderate AR and in combination
with INS for moderate to severe disease.47 Sedating antihista-
mines, all of which cause psychomotor retardation, should no
longer be used.48 Intranasal antihistamine alone is faster in
onset (15 min, compared with 1 h) and is more effective on
nasal symptoms than oral antihistamines49 and is underused.
INS are superior, for all symptoms, (excluding eye symptoms
for which they are equal) to antihistamines (oral or topical), to
antileukotrienes and to the combination of antihistamine and
antileukotriene in meta-analyses.50–52 In particular, they are
more effective in relieving nasal obstruction.50 INS are recom-
mended for moderate to severe disease; concerns relating to sys-
temic effects are unfounded when the latest molecules are used,
as their systemic bioavailability is extremely low (ﬁgure 3).
Mometasone furoate and ﬂuticasone proprionate have been
extensively studied in children, and no adverse effects on corti-
sol levels, the hypothalamic-pituitary-adrenal axis or growth
Figure 2 Entry to therapy can occur at 1, 2 or 3 year, depending on severity of presenting symptoms. Poor control should lead to a step up, good
control to a step down, so that the minimum therapy necessary is used. For seasonal disease, regular therapy should be commenced 2 weeks before
the anticipated start of symptoms. *Oral antihistamines may be better tolerated, while intranasal antihistamines have a more rapid onset of action.
**Reconsider diagnosis if not controlled within 1–2 weeks. If <2 years of age and unresponsive to antihistamine within a week, reconsider
diagnosis before stepping up therapy. If poorly controlled, consider a short rescue course of a decongestant or low-dose oral prednisolone to gain
symptom control; topical ipratropium may be useful for rhinorrhoea (adapted from Roberts et al [33] (with permission)).
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over 1 year have been detected,53 54 unlike beclamethasone.55
Fluticasone furoate, similarly, has low bioavailability, but the use
of a double-dose 110 mcg per day has been associated with
reduction in growth.56 It is sensible to use the lowest dose of
minimally bioavailable INS needed to maintain control and to
administer this in the morning. ‘Holidays’ from treatment are
ineffective in reduction of systemic effects and are liable to
result in loss of control. Regular monitoring of growth is a sen-
sitive marker for systemic effects and is sensible, particularly in
children receiving corticosteroids to skin, lung and nose. The
contribution to systemic effects is greater from skin than lung,
with very little from the nose compared with skin or lung, so if
growth is slowed, attempts to reduce those areas of treatment
should be made ﬁrst. Considering the adverse impact of uncon-
trolled rhinitis upon asthma, it may be possible to reduce or
even stop inhaled corticosteroids once INS are started, since
INS may reduce ocular symptoms and also bronchial hyper-
reactivity, probably by reduction of inﬂammation-induced neural
reﬂexes,57 at which recently available molecules such as ﬂutica-
sone furoate appear more consistently effective.58 There is some
evidence that INS can beneﬁt asthma,17 59–61 but randomised,
controlled prospective trials are needed of the addition of long-
term INS to regular inhaled corticosteroids, both for efﬁcacy
and safety. It is logical to treat AR and asthma as one with a cor-
ticosteroid inhaled via the nose. Attempts have been made,62 63
but the practice has not yet been accepted.
It is vital to explain the safety and correct use of INS to chil-
dren and their carers. The delay in onset of action should be
explained, plus the need for regular treatment, how to adminis-
ter the spray (ﬁgure 4) and linking use to a regular daily activity,
such as teeth cleaning. Provision of contact details for advice
should also aid concordance, since well-meaning uninformed
relatives, friends and even primary care practitioners may state
that temporary use is all that is allowed, or may switch the pre-
scription to an older, cheaper, more bioavailable molecule.
Nasal biopsies do not show mucosal atrophy after 1 year of
regular INS use in adults.64–66 INS improve mucociliary clear-
ance, and have shown beneﬁts when used in acute rhinosinusitis,
so continuation during viral colds is recommended.
A combined nasal spray containing ﬂuticasone propionate and
azelastine, an antihistamine, is under trial for use in children.
Systemic corticosteroid is available as a brief rescue therapy
for very severe symptoms, the lowest dose for the shortest
time should be accompanied by an INS. Depot corticosteroid
injections are not recommended, as risk outweighs
beneﬁt.33 67
Leukotriene receptor antagonists have similar effects as oral
antihistamines, with minimal additional beneﬁt when the two
are used in combination.33 68 Use in children with seasonal AR,
in preschool children with persistent AR and in children with
AR and concomitant asthma, where concerns exist about the
use of glucocorticoids, is suggested by ARIA 2010.
ALLERGEN-SIT
At present, this is recommended for severe AR uncontrolled by
pharmacotherapy.33 There is good evidence in pollen-induced
AR that SIT reduces symptoms in the nose and eyes.69–71 In
some trials, SIT improves allergic asthma.69–71
SIT can be subcutaneous or sublingual. Currently, only 1%–
5% of European children suffering with AR are treated with
SIT: with 75% receiving subcutaneous immunotherapy (SCIT)
and 25% sublingual immunotherapy (SLIT).71
Beneﬁts of therapy must always be weighed against risks.
A recent review of UK SIT practice72 conﬁrmed a low inci-
dence of severe adverse reactions and no fatalities, even
though guidelines about excluding chronic asthma subjects
were not observed, and patients with chronic asthma were
treated with SIT. Adrenaline injections are still sometimes
Figure 4 (A) shows how to use a nasal spray so as to avoid the
septum and spray as much of the lateral wall mucosa as possible,
allowing subsequent mucociliary clearance to distribute the liquid all
over the mucosa. (B) shows how nasal drops (superior for
rhinosinusitis) should be used with the head completely upside down
so that drops reach the ostiomeatal complex in the upper nose where
sinuses drain and ventilate (adapted from Scadding et al [1] (with
permission)).
Figure 3 Systemic bioavailability of intranasal steroids.
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needed for anaphylaxis in SCIT which, because it is not com-
pletely risk-free, must only be administered by those compe-
tent in its use.
SLIT in children shows efﬁcacy in hay fever; HDM desensi-
tisation gives variable results.73 74 Local reactions are common
with itching and swelling in mouth and throat, worst on ﬁrst
application and usually disappearing in 2 weeks, systemic reac-
tions rarely occur and no fatalities have been reported. A meta-
analysis of 49 SLIT studies, including 15 paediatric papers with
over 1400 children, suggests that it is more effective in the
paediatric group.75
SIT is the only treatment with a disease-modifying effect
during the treatment period and in the years following. It
appears to be capable of preventing the progression of rhinitis
to asthma and new allergic sensitisations. The Prevention of
Asthma Study demonstrated a reduction in cases of new asthma
in children receiving 3 years of SCIT for hay fever at 3, 5 and
10 years, compared with those treated by pharmacotherapy
alone,19 but was not blinded. A double-blind, randomised trial
is in progress to test the effectiveness of grass pollen SLIT in
asthma prevention. Another is in progress comparing the efﬁ-
cacy of SCIT and SLIT. It seems likely that SIT administered cor-
rectly to appropriately selected patients is socioeconomically
beneﬁcial.75
Concordance with long-term therapy, like SIT, is challenging:
good contact and communication are again necessary.
CONCLUSION
AR is worth treating effectively, even when it is part of a myriad
of allergic conditions; as the nose is the gateway to the respira-
tory tract, good rhinitis control can facilitate control of symp-
toms elsewhere. AR, if poorly controlled, results in troublesome
symptoms and impacts on daily activities, quality of life and on
other areas of the respiratory tract, such as ears, sinuses, throat
and lungs. Possible causes for difﬁcult-to-treat cases include
doctor factors such as misdiagnosis and undertreatment or
patient factors such as lack of concordance with therapy. This
can be reduced by information leaﬂets on speciﬁc allergen
avoidance, the correct technique in the application of nasal pre-
parations (avoiding the septum and leaving in place rather than
snifﬁng back) and explanation of potential side effects. Clearly
written treatment plans are useful, particularly if several pre-
parations are prescribed.
AR can sometimes copresent in association with other forms
of rhinitis (or rhinosinusitis) leading to increased severity
(mixed rhinitis). Associated comorbidities should be considered
in the differential diagnosis in order to determine the most
appropriate therapeutic approach. Allergen-SIT should be con-
sidered for patients with genuinely difﬁcult-to-control allergic
disease, despite guideline-directed pharmacotherapy properly
taken. Grade A evidence via meta-analysis conﬁrms its efﬁcacy
and it is unique in its ability to alter the long-term disease
course.
Local primary care directives, such as use of the cheapest, sig-
niﬁcantly bioavailable INS and inhaled corticosteroids mole-
cules, and minimal provision of SIT are misguided and liable to
result in extra-disease manifestations, reduced quality of life,
and will increase costs in the long term.76
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